PCVX vs. FMTX, SRRK, EDIT, ADVM, SGMO, ARGX, BNTX, NBIX, TECH, and QGEN
Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Forma Therapeutics (FMTX), Scholar Rock (SRRK), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), and Qiagen (QGEN). These companies are all part of the "biological products, except diagnostic" industry.
Forma Therapeutics (NASDAQ:FMTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
87.4% of Forma Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 5.8% of Forma Therapeutics shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Forma Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Forma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vaxcyte has a consensus price target of $78.50, suggesting a potential upside of 11.71%. Given Forma Therapeutics' higher probable upside, analysts plainly believe Vaxcyte is more favorable than Forma Therapeutics.
In the previous week, Vaxcyte had 7 more articles in the media than Forma Therapeutics. MarketBeat recorded 7 mentions for Vaxcyte and 0 mentions for Forma Therapeutics. Forma Therapeutics' average media sentiment score of 1.32 beat Vaxcyte's score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media.
Forma Therapeutics has a beta of -0.94, meaning that its stock price is 194% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Forma Therapeutics' return on equity of -28.83% beat Vaxcyte's return on equity.
Vaxcyte received 3 more outperform votes than Forma Therapeutics when rated by MarketBeat users. Likewise, 68.75% of users gave Vaxcyte an outperform vote while only 51.72% of users gave Forma Therapeutics an outperform vote.
Summary
Vaxcyte beats Forma Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Vaxcyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
